This announcement is a separate document:
自愿披露关于西格列他钠联合二甲双胍治疗2型糖尿病适应症获批的公告
Voluntary disclosure of the announcement regarding the approval of the indications for the use of empagliflozin and metformin hydrochloride in the treatment of type 2 diabetes.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated